Skip to content

Omeros gets breakthrough FDA tag; Cantor remains neutral

June 14, 2017

Shares of Omeros Corporation OMER 14.5% soared higher by more than 15 percent on Tuesday after the U.S. Food and Drug Administration granted a breakthrough therapy designation to the company’s treatment of Immunoglobulin A nephropathy called OMS721.

The FDA’s designation provides Omeros with several positive benefits, including increased regulatory access and an opportunity for an accelerated priority review, Cantor Fitzgerald’s Elemer Piros commented in a research report. The designation also helps validate the initial data demonstrated by OMS721 and increases the analyst’s focus on ongoing Phase 3 programs.

Despite the encouraging update, Omeros’ stock remains Neutral rated with a $15 price target, which implies notable downside from Tuesday’s trading action where shares hit a new 52-week high of $19.95 (see Elemer Piros‘ track record).

However, the analyst may become incrementally bullish, as the company is expected to offer additional clarity and progress across its three emerging Phase 3 clinical programs with OMS721, which serves as a potential driver for the stock.

“As a reminder, OMS721 is being developed across three indications,” the analyst explained. “Atypical hemolytic uremic syndrome (aHUS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and IgAN.”

Finally, the analyst ascribes $150 million in value to Omeros’ entire pipeline and discovery platform, but there is the possibility for further upside as the company progresses in its pipeline development.

At last check, shares of Omeros were up 12.52 percent at $19.24.

 

Latest Ratings for OMER

Date Firm Action From To
May 2017 Cantor Fitzgerald Downgrades Buy Neutral
Jun 2016 Cantor Fitzgerald Initiates Coverage on Buy
Apr 2016 Roth Capital Terminates Buy

http://bit.ly/2rZtza7

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: